GlassScriptPhysician profile
Katherine Allen Gamper
NPI 1124417159
$3,876.30
in general payments reported to CMS, 2019-2025
26 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,056 · 2022: $1,074 · 2023: $1,221 · 2024: $232 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.27 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.20 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $368.74 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $364.44 | 2021-2023 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $265.90 | 2021-2023 | Dupixent |
| Genzyme Corporation | $225.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $224.63 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $174.41 | 2021-2023 | Taltz |
| Leo Pharma INC. | $137.93 | 2021-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $126.50 | 2021-2023 | Winlevi, Absorica Ld, Ilumya |
| Sanofi-Aventis U.S. LLC | $120.57 | 2021 | |
| Incyte Corporation | $77.54 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.49 | 2024-2025 | |
| Pfizer INC. | $69.64 | 2021-2025 | |
| Novo Nordisk INC | $68.01 | 2024-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $57.57 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $55.30 | 2023-2024 | Zoryve |
| Ucb, INC. | $51.68 | 2021-2022 | |
| Dermavant Sciences, INC. | $41.32 | 2023 | Vtama |
| Amgen INC. | $38.57 | 2023-2024 | Otezla, Repatha |
| Galderma Laboratories, L.P. | $25.42 | 2021 | |
| Epi Health, LLC | $24.67 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $20.89 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.65 | 2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.68 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Gamper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.